[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369577-105":59,"doc-detail-369577-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","exploring-t-cell-bispecific-antibodies-in-gynecologic-malignancy","Exploring T-cell bispecific antibodies in gynecologic malignancy","","Gynecologic cancers challenge women’s health due to frequent relapse despite surgery, chemotherapy, and radiation, making innovative therapies essential. This review focuses on T-cell bispecific antibodies (TCBs), which bind tumor-associated antigens and activate T cells to induce tumor cell lysis. It summarizes mechanisms of action, preclinical and clinical evidence, and safety considerations, including cytokine release syndrome and on-target off-tumor toxicity. Preclinical work highlights targets such as AXL, MUC1, LYPD1, and MUC16 in ovarian cancer, while ongoing trials assess MUC16-targeted TCBs in ovarian and endometrial cancers, positioning TCBs as a promising off-the-shelf immunotherapy requiring further optimization.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-t-cell-bispecific-antibodies-in-gynecologic-malignancy/369577/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-t-cell-bispecific-antibodies-in-gynecologic-malignancy/369577.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are new treatments needed for gynecologic malignancies?","Question",{"text":113,"@type":114},"Relapse remains common despite conventional surgery, chemotherapy, and radiation. The review emphasizes the need for innovative strategies to improve outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do T-cell bispecific antibodies work against tumors?",{"text":118,"@type":114},"TCBs bind tumor-associated antigens and T cells simultaneously, triggering T-cell activation and tumor cell lysis.",{"name":120,"@type":111,"acceptedAnswer":121},"What advantages do TCBs have compared with CAR T-cell therapy?",{"text":122,"@type":114},"TCBs are available as off-the-shelf products, avoiding long manufacturing times and often showing lower rates of severe CRS or neurotoxicity, with the option to discontinue treatment if needed.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369577,1790294974,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Gynecologic Oncology Reports 59 (2025) 101772  \nContents lists available at ScienceDirect  \nGynecologic Oncology Reports  \njournal [homepage:](homepage: www.elsevier.com/locate/gynor)[ www.elsevier.com/locate/gynor](homepage: www.elsevier.com/locate/gynor)  \n| Exploring T-cell bispecific antibodies in gynecologic malignancy\u003Cbr>*\u003Cbr>Emily O’Brien , Christopher M. Mayer , Rebecca C Arend\u003Cbr>Department of Gynecologic Oncology, University of Alabama at Birmingham School of Medicine and O’Neal Comprehensive Cancer Center, Birmingham, AL, United States of America |\n| --- |\n| A B S T R A C T |\n| Gynecologic cancers present a significant challenge to women’s health, necessitating innovative therapeutic strategies due to high relapse rates despite conventional treatments. Immunotherapy, particularly T-cell bispecific antibodies (TCBs), offers a promising approach by redirecting the immune system to target and eliminate tumor cells. TCBs bind simultaneously to tumor-associated antigens and T cells, inducing T-cell activation and tumor cell lysis. While CAR T-cell therapies have shown success in hematologic malignancies, TCBs offer advantages such as being “off-the-shelf” products with lower rates of severe toxicities. This review provides an overview of TCBs in gynecologic malignancies, focusing on their mechanisms of action, preclinical and clinical data, and safety profiles, while also addressing the challenges and future directions. Preclinical data highlight TCBs targeting AXL, MUC1, LYPD1, and MUC16 in ovarian cancer, demonstrating potent antitumor activity. Clinical trials evaluating MUC16-targeted TCBs in ovarian and endometrial cancers are ongoing. The safety profile of TCBs includes risks such as cytokine release syndrome and on-target off-tumor toxicity, which require careful management. TCBs represent a promising immunotherapeutic approach for gynecologic cancers, warranting further investigation to optimize their efficacy and safety. |\n\n1. Introduction  \nGynecologic cancers, including ovarian/fallopian tube/primary peritoneal, endometrial, cervical, vulvar/vaginal, and gestational trophoblastic cancers, pose a significant threat to women’s health worldwide. In 2024, it was estimated that there would be over 120,000 new cases of gynecologic malignancy diagnosed and approximately 40,000 deaths in the U.S (SEER, 2023). Traditional treatments such as surgery, chemotherapy, and radiation have improved survival outcomes, but many women still experience relapse and succumb to the disease, underscoring the need for innovative therapeutic strategies.  \nCancer immunotherapy has given hope to patients with advanced oncological and immunological indications over the past 40 years. This evolution has transformed the landscape of cancer treatment in a targeted and effective manner, exemplified by the development and approval of monoclonal antibodies (mAbs; first approved in 1986), antibody-drug conjugates (ADCs; first approved in 2000), T-cell- bispecific antibodies (TCBs; first approved in 2014), and chimeric antigen receptor T lymphocytes (CAR-Ts; first approved in 2017). To date, the US FDA has approved six CAR-T products and more than one hundred mAbs for clinical use. There are currently 5 FDA approved TCBs approved for multiple myeloma, uveal melanoma, diffuse large B-Cell lymphoma, and B-Cell acute lymphoblastic leukemia (ALL). (Jen et al., 2018; O’Leary et al., 2019; Ma et al., 2019; Jen et al., 2019).  \nTwo of the more recent T-cell therapeutic strategies have emerged  \nthat redirect T cells to tumor cells, regardless of their T-cell receptor specificity: chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody TCB treatment. CAR T cells are genetically modified to express a CAR specific to a tumor-associated antigen, triggering T-cell signaling and tumor cell elimination (Sterner and Sterner, 2021). Several CAR T-cell therapies have received regulatory approval for treating patients with B-cell acute lymphoblastic ","cbCait3qL8oY7F6p","https://ap.wps.com/l/cbCait3qL8oY7F6p","pdf",1304484,"English","# Introduction\n# Mechanisms and rationale for TCBs\n# Preclinical targets in gynecologic cancers\n# Clinical trial status and safety considerations","[{\"question\":\"Why are new treatments needed for gynecologic malignancies?\",\"answer\":\"Relapse remains common despite conventional surgery, chemotherapy, and radiation. The review emphasizes the need for innovative strategies to improve outcomes.\"},{\"question\":\"How do T-cell bispecific antibodies work against tumors?\",\"answer\":\"TCBs bind tumor-associated antigens and T cells simultaneously, triggering T-cell activation and tumor cell lysis.\"},{\"question\":\"What advantages do TCBs have compared with CAR T-cell therapy?\",\"answer\":\"TCBs are available as off-the-shelf products, avoiding long manufacturing times and often showing lower rates of severe CRS or neurotoxicity, with the option to discontinue treatment if needed.\"}]","Exploring T-cell bispecific antibodies in gynecologic malignancy | PDF",1790183509,15,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fa3da02e0b6011dc4d1a4acdd428109.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11e5f88f1e0f52e1b651d76f24691510.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca45d9f343ce2a569e2c22f7f79c1278.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/538eef0117eb47e6550224934e356375.webp",980,1306]